Clinical studies have demonstrated that SGLT2i lead to a decrease in insulin secretion, enhanced beta-cell function and insulin sensitivity, with a demonstrated decrease of renin-angiotensin and sympathetic vasomotor system activity that has provided a demonstrated additive advantage for retinopathy (211). Here, INS is linked to retinal disorder.